Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Amanda Mocroft
  • Peter Reiss
  • Kirk, Ole
  • Cristina Mussini
  • Enrico Girardi
  • Philippe Morlat
  • Christoph Stephan
  • Stephane De Wit
  • Katja Doerholt
  • Jade Ghosn
  • Heiner C Bucher
  • Lundgren, Jens
  • Genevieve Chene
  • Jose M Miro
  • Hansjakob Furrer
  • Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)
Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
TidsskriftClinical Infectious Diseases
Udgave nummer5
Sider (fra-til)611-9
Antal sider9
StatusUdgivet - 1 sep. 2010

ID: 33863666